Drug Trial Radar · NCT06963502
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
762
Planned (sponsor's estimate)
Start
May 30, 2025
Primary completion
Dec 31, 2028
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in and Colorectal cancer(CRC) and non-Small cell lung cancer (NSCLC).
Conditions
- Advanced Solid Tumors
- Colorectal Cancer
- Non-Small Cell Lung Cancer
Interventions
HS-10370Drug
Participants will receive HS-10370 dose 1 administered orally
HS-20117Drug
Participants will receive HS-20117 given as dose 3 intravenous infusion(IV) once every 14-day cycle.
AdebrelimabDrug
Participants will receive Adebrelimab intravenous infusion(IV) once every 21-day cycle
CapecitabineDrug
Participants will receive Capecitabine administered orally
OxaliplatinDrug
Participants will receive Oxaliplatin intravenous infusion(IV) once every 21-day cycle.
Folinic Acid, Fluorouracil and Oxaliplatin/IrinotecanDrug
Participants will receive Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan intravenous infusion(IV) once every 14-day cycle.
HS-20093Drug
Participants will receive HS-20093 intravenous infusion(IV) once every 21-day cycle
platinum (cisplatin or carboplatin)Drug
Participants will receive platinum (cisplatin or carboplatin) administered IV in 21-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Event(s) (AEs)Time frame: From Cycle 1 Day 1 (C1D1) to disease progression or death, up to 2 years (each cycle is 14 days).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Sun Yat-sen University Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.